Abstract Commentary:Association Between Patient-Reported Outcomes and Changes in Prostate-Specific Antigen in Patients with Advanced Prostate Cancer Treated with Apalutamide in the Spartan and Titan Studies

Posted by Benjamin H. Lowentritt, MD, FACS | Jul 2022

Benjamin H. Lowentritt, MD, FACS, presented “Abstract Commentary:Association Between Patient-Reported Outcomes and Changes in Prostate-Specific Antigen in Patients with Advanced Prostate Cancer Treated with Apalutamide in the Spartan and Titan Studies” during the 32nd Annual International Prostate Cancer Update (IPCU32) conference on March 8, 2022, in Snowbird, Utah.

How to cite: Lowentritt, Benjamin H. “Abstract Commentary:Association Between Patient-Reported Outcomes and Changes in Prostate-Specific Antigen in Patients with Advanced Prostate Cancer Treated with Apalutamide in the Spartan and Titan Studies” March 8, 2022. Accessed May 2024. https://grandroundsinurology.com/abstract-commentaryassociation-between-patient-reported-outcomes-and-changes-in-prostate-specific-antigen-in-patients-with-advanced-prostate-cancer-treated-with-apalutamide-in-the-spartan-and-titan/

About the 32nd Annual International Prostate Cancer Update (IPCU32):
Presented by Program Chair E. David Crawford, MD, The International Prostate Cancer Update (IPCU), is a multi-day, CME-accredited conference focused on new developments in prostate cancer treatment, diagnosis, and prevention. IPCU 32 featured lectures, interactive discussions, panel roundtables, debates, and case reports. This conference was led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.

About The Author

Benjamin H. Lowentritt, MD, FACS

Benjamin H. Lowentritt, MD, FACS, is Director of Prostate Cancer Services for United Urology Group, the leading network of urologists in the United States. He previously served as the Director of the Prostate Cancer Care Program and Director of Minimally Invasive Surgery and Robotics at Chesapeake Urology, one of United Urology’s group practices. Dr. Lowentritt is also a member of United Urology’s Executive Clinical Team. Dr. Lowentritt earned his medical degree from Baylor College of Medicine in Houston, Texas. He completed his medical residency at the University of Maryland School of Medicine and a fellowship in robotic, laparoscopic, and endoscopic urology at Tulane University. He has served on the board of the Mid-Atlantic Section of the American Urological Association, as well as on the Boards of Directors for MedChi, the Maryland State Medical Society, and the Baltimore City Medical Society.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat